DBV Technologies S.A.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing Viaskin, an epicutaneous patch platform designed to deliver allergens through the skin. Its lead program, Viaskin Peanut, is being advanced for peanut allergy in children, with the company focused on late-stage clinical development, regulatory filings, and commercial readiness in the United States and Europe.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead product candidate for peanut allergy treatment using an epicutaneous patch.
Broader patch-based allergy immunotherapy technology and related pipeline work.
Clinical trials, FDA/EMA interactions, and BLA/MAA preparation work.
Third-party manufacturing, quality control, and pre-commercial supply commitments.
Customers
DBV does not sell a broad commercial product portfolio today; its primary end customers are patients with peanut allergy, especially children, if Viaskin Peanut is approved. In the current stage, the company’s main counterparties are regulators, clinical investigators, and manufacturing partners rather than paying end-users. Future commercial demand would come from physicians, allergy specialists, and healthcare systems that prescribe and reimburse the patch.
Families seeking a non-oral immunotherapy option for peanut allergy, especially pediatric patients targeted by Viaskin Peanut.
Clinicians who would prescribe the patch if approved and drive adoption through treatment protocols.
FDA and EMA review the clinical package, safety data, and manufacturing readiness before approval.
Hospitals and research centers that enroll patients and generate efficacy/safety evidence.
Third-party API and device manufacturers that enable clinical supply and future commercialization.
Strategy
DBV’s strategy is to complete late-stage development of Viaskin Peanut, secure regulatory approval, and prepare for a U.S. launch if the program succeeds. The company is also strengthening manufacturing and supply arrangements with Sanofi and other partners so it can support commercial-scale production and reduce execution risk ahead of a potential approval.
Positive pivotal data is needed to support regulatory submissions and commercial value creation.
BLA and potential EU submission are the gatekeepers to commercialization.
Commercial launch requires reliable third-party production and inventory availability.
The company is still pre-commercial and needs external capital to fund operations.
Geography
The company is operationally split between the United States and Europe, with a primary U.S. office in Warren, New Jersey and additional North American facilities. Its active pharmaceutical ingredient for Viaskin Peanut is manufactured in France, and the company relies on European and other non-U.S. suppliers for critical raw materials and clinical inputs. Geography matters because regulatory strategy is centered on the U.S. BLA path and the European MAA path, while supply-chain exposure is concentrated in cross-border manufacturing and sourcing.
Risks
DBV remains a pre-commercial biotech with substantial going-concern risk, so its value depends heavily on clinical success, regulatory approval, and access to capital. The company also depends on third-party manufacturing and cross-border sourcing, which creates supply-chain, tariff, and execution risk as it moves toward potential commercialization.
- Going-concern and liquidity riskImpact: CriticalLikelihood: High
The company disclosed substantial doubt about its ability to continue as a going concern due to operating losses and liquidity challenges.
Exposure: Corporate funding and continuity of operations
- Regulatory approval riskImpact: HighLikelihood: High
The company needs FDA and potentially EMA acceptance of its clinical package and manufacturing readiness.
Exposure: BLA and MAA submissions
- Third-party manufacturing dependenceImpact: HighLikelihood: High
DBV does not own manufacturing facilities and relies on external suppliers for API and patch production.
Exposure: Sanofi supply chain and non-U.S. vendors
- Clinical development failureImpact: High
Viaskin Peanut depends on positive pivotal and supporting study results to justify filing and approval.
Exposure - Dilution from financing activitiesImpact: High
ATM sales and warrant exercises can fund operations but may dilute existing shareholders.
Exposure: Equity issuance and warrant overhang
- Tariffs and trade restrictionsImpact: MediumLikelihood: Medium
Cross-border sourcing of API, raw materials, and lab inputs could raise costs and disrupt timelines.
Exposure
Accounting
Judgemental itemsClinical, regulatory, and pre-commercial activities are expensed as incurred, so trial timing drives quarterly volatility.
Impact: Affects operating loss and comparability across periods
Minimum purchase levels and service fees under the Sanofi agreement may create future obligations and expense recognition.
Impact: Can affect liabilities, R&D expense, and cash needs
Management must assess whether available cash and financing plans are sufficient to fund operations.
Impact: Important for liquidity analysis and valuation
ATM sales and warrant exercises change share count and can affect capital structure presentation.
Impact: Dilution and cash runway analysis
Office moves and leased facilities create recurring occupancy costs and right-of-use asset/liability balances.
Impact: Affects G&A expense and cash flow
Similar listed companies
Publicly listed companies with a comparable business focus.
Dianthus Therapeutics, Inc.
DNTH · Pharmaceutical Preparations
Dianthus Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for autoimmune and inflammatory diseases.
Davion Healthcare PLC
DAVI · Surgical & Medical Instruments & Apparatus
Davion Healthcare Plc is an Ireland-based healthcare company focused on developing and commercialising healthcare technologies and products.
Dynavax Technologies Corp
Pharmaceutical Preparations
Krystal Biotech, Inc.
KRYS · Biological Products, (No Diagnostic Substances)
Krystal Biotech is a commercial-stage biotechnology company that develops and sells genetic medicines built on an engineered HSV-1 gene therapy platform.
Dyadic International, Inc
DYAI · Biological Products, (No Diagnostic Substances)
Dyadic International is a U.S.-based biotechnology platform company that develops microbial protein production systems for industrial, life sciences, food and…
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
Last updated: 24/09/2026